Increases m soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b

Annals of Neurology

Volumn 41, Issue 5, 1997, Pages 669-674

  Calabresi, Peter A ^a,b   Tranquill, Laura R ^a   Dambrosia, James M ^b   Stone, Lael A ^c   Maloni, Heidi ^a   Bash, Craig N ^a   Frank, Joseph A ^a   McFarland, Henry F ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON BETA SERINE; L SELECTIN; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GADOLINIUM PENTETATE; INTERFERON BETA-1B; MEGLUMINE; NERVE CELL ADHESION MOLECULE; ORGANOMETALLIC COMPOUND; PENTETIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL ADHESION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DEMYELINATING DISEASE; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOREGULATION; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; BRAIN; CEREBROSPINAL FLUID; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; IMAGE ENHANCEMENT; METHODOLOGY; PATHOLOGY; UPREGULATION;

ADULT; BIOLOGICAL MARKERS; BRAIN; CELL ADHESION MOLECULES, NEURONAL; CEREBROSPINAL FLUID; CONTRAST MEDIA; DRUG COMBINATIONS; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MULTIPLE SCLEROSIS; ORGANOMETALLIC COMPOUNDS; PENTETIC ACID; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0030610524     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410410517     Document Type: Article

References (28)

1. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10: 153-187
2. Williams KC, Ulvestad E, Hickey WF. Immunology of multiple sclerosis. Clin Neurosci 1994;2:229-245
3. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte immigration: the multiple step paradigm. Cell 1994; 76:301-314
4. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993;11:767-804
5. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-2101
6. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:506-512
7. Pigott R, Dillon LP, Hemingway IH, Gearing AJH. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatant cytokine-activated cultured endothelial cells. Biochem Biophys Res Commun 1992;187:584-589
8. Hartung H-P, Reiners K, Archelos JJ, et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995;38:186-193
9. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N. Soluble E-selectin in the serum and cerebrospinal fluid of patients with multiple sclerosis and HTLV-1 associated myelopathy. Neurology 1995;45:1914-1918
10. Rieckmann P, Martin S, Weischelbraun I, et al. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: clCAM-1 is an indicator for relapse. Neurology 1994;44:2367-2372
11. Kermode AG, Thompson JA, Tofts PS, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenesis and clinical implications. Brain 1990;113:1477-1489
12. Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34: 661-669
13. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadolinium enhancing MRI lesions. Ann Neurol 1993;33: 480-489
14. The Interferon β Multiple Sclerosis Study Group. Interferon beta 1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind placebo controlled trial. Neurology 1993;43:655-661
15. Paty DW, Li DKB, MS/MRI Study Group, IFN-β MS Study Group. Interferon beta 1b is effective in relapsing and remitting multiple sclerosis. 2: MRI analysis results of a multi-center, randomized, double-blind, placebo controlled trial. Neurology 1993;43:662-667
16. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-619
17. Noronha A, Toscas A, Jensen MA. Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J Neuroimmunol 1993;46:145-154
18. Panitch HS, Folus JS, Johnson KP. Recombinant beta interferon inhibits gamma interferon production in multiple sclerosis. Ann Neurol 1987;22;139
19. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
20. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452
21. McCullagh P, Neider JA. Generalized linear models. 2nd ed. London: Chapman and Hall, 1989
22. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-435
23. Dore-Duffy P, Newman W, Balabarov R, et al. Circulating soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity. Ann Neurol 1995;37:55-62
24. Matsuda M, Tsukada N, Koichi M, Yanagisawa N. Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy. J Neuroimmunol 1995;59:35-40
25. Barten DM, Ruddle NH. Vascular cell adhesion molecule-1 modulation by tumor necrosis factor in experimental allergic encephalomyelitis. J Neuroimmunol 1994;51:123-133
26. Soilu-Hanninen M, Salmi A, Salonen R. Interferon-B downregulates expression of VLA-4 antigen and antagonizes interferon gamma induced expression of HLA-DQ on human peripheral blood monocytes. J Neuroimmunol 1995;60: 99-106
27. Dayal AS, Jensen MA, Lledo A, Arnason BGW. Interferon-gamma secreting cells in multiple sclerosis patients treated with interferon-beta 1b. Neurology 1995;45:2173-2177
28. Neish AS, Read MA, Thanos D, et al. Endothelial interferon regulatory factor 1 cooperates with NF-κB as a transcriptional activator of vascular cell adhesion molecule 1. Mol Cell Biol 1995;15:2558-2569